119 related articles for article (PubMed ID: 3034423)
1. Phase II trial of etoposide in the management of advanced or recurrent mixed mesodermal sarcomas of the uterus: a Gynecologic Oncology Group Study.
Slayton RE; Blessing JA; DiSaia PJ; Christopherson WA
Cancer Treat Rep; 1987 Jun; 71(6):661-2. PubMed ID: 3034423
[No Abstract] [Full Text] [Related]
2. Phase II trial of etoposide in the management of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study.
Slayton RE; Blessing JA; Delgado G
Cancer Treat Rep; 1982 Aug; 66(8):1669-71. PubMed ID: 7105059
[No Abstract] [Full Text] [Related]
3. Phase II trial of etoposide in the management of advanced and recurrent leiomyosarcoma of the uterus: a Gynecologic Oncology Group Study.
Slayton RE; Blessing JA; Angel C; Berman M
Cancer Treat Rep; 1987 Dec; 71(12):1303-4. PubMed ID: 3690545
[No Abstract] [Full Text] [Related]
4. Phase II trial of etoposide in the management of advanced or recurrent squamous cell carcinoma of the vulva and carcinoma of the vagina: a Gynecologic Oncology Group Study.
Slayton RE; Blessing JA; Beecham J; DiSaia PJ
Cancer Treat Rep; 1987 Sep; 71(9):869-70. PubMed ID: 3621221
[No Abstract] [Full Text] [Related]
5. Prolonged oral etoposide in recurrent or advanced leiomyosarcoma of the uterus: a gynecologic oncology group study.
Rose PG; Blessing JA; Soper JT; Barter JF
Gynecol Oncol; 1998 Aug; 70(2):267-71. PubMed ID: 9740703
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of hydroxyurea, dacarbazine (DTIC), and etoposide (VP-16) in mixed mesodermal tumors of the uterus: a Gynecologic Oncology Group study.
Currie JL; Blessing JA; McGehee R; Soper JT; Berman M
Gynecol Oncol; 1996 Apr; 61(1):94-6. PubMed ID: 8626125
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of cisplatin in the treatment of patients with advanced or recurrent mixed mesodermal sarcomas of the uterus: a Gynecologic Oncology Group Study.
Thigpen JT; Blessing JA; Orr JW; DiSaia PJ
Cancer Treat Rep; 1986 Feb; 70(2):271-4. PubMed ID: 3948191
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of etoposide in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study.
Thigpen T; Blessing JA; Yordan E; Valea F; Vaccarello L
Gynecol Oncol; 1996 Oct; 63(1):120-2. PubMed ID: 8898180
[TBL] [Abstract][Full Text] [Related]
9. Phase II evaluation of oral trimetrexate in mixed mesodermal tumors of the uterus: a gynecologic oncology group study.
Fowler JM; Blessing JA; Burger RA; Malfetano JH
Gynecol Oncol; 2002 May; 85(2):311-4. PubMed ID: 11972393
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of etoposide in the management of advanced or recurrent non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study.
Slayton RE; Blessing JA; Homesley HD
Cancer Treat Rep; 1984 Dec; 68(12):1513-4. PubMed ID: 6509456
[No Abstract] [Full Text] [Related]
11. Mitoxantrone in the treatment of advanced uterine sarcoma. A phase II trial of the Gynecologic Oncology Group.
Muss HB; Bundy BN; Adcock L; Beecham J
Am J Clin Oncol; 1990 Feb; 13(1):32-4. PubMed ID: 2154921
[TBL] [Abstract][Full Text] [Related]
12. Phase II evaluation of liposomal doxorubicin (Doxil) in recurrent or advanced leiomyosarcoma of the uterus: a Gynecologic Oncology Group study.
Sutton G; Blessing J; Hanjani P; Kramer P;
Gynecol Oncol; 2005 Mar; 96(3):749-52. PubMed ID: 15721421
[TBL] [Abstract][Full Text] [Related]
13. Prolonged oral etoposide in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study.
Rose PG; Blessing JA; Van Le L; Waggoner S
Gynecol Oncol; 1998 Aug; 70(2):263-6. PubMed ID: 9740702
[TBL] [Abstract][Full Text] [Related]
14. Paclitaxel in the treatment of carcinosarcoma of the uterus: a gynecologic oncology group study.
Curtin JP; Blessing JA; Soper JT; DeGeest K
Gynecol Oncol; 2001 Nov; 83(2):268-70. PubMed ID: 11606082
[TBL] [Abstract][Full Text] [Related]
15. Tamoxifen in advanced and recurrent uterine sarcomas: a phase II study. Gynecological Group, Clinical Oncological Society of Australia and the Cancer Institute, Melbourne, Australia.
Cancer Treat Rep; 1986 Jun; 70(6):811-2. PubMed ID: 3731142
[No Abstract] [Full Text] [Related]
16. [Malignant mixed mesodermal tumor of the uterus. A contribution on extraosseous osteoblastic sarcomas].
Thurner J; Montano A
Wien Med Wochenschr; 1977 Apr; 127(7):232-6. PubMed ID: 193306
[No Abstract] [Full Text] [Related]
17. Adjuvant ifosfamide and cisplatin in patients with completely resected stage I or II carcinosarcomas (mixed mesodermal tumors) of the uterus: a Gynecologic Oncology Group study.
Sutton G; Kauderer J; Carson LF; Lentz SS; Whitney CW; Gallion H;
Gynecol Oncol; 2005 Mar; 96(3):630-4. PubMed ID: 15721404
[TBL] [Abstract][Full Text] [Related]
18. [Mixed mesodermal tumors of the uterus].
Cupr Z; Dvorák P; Rohanová M; Siska A
Zentralbl Gynakol; 1972 Sep; 94(35):1137-45. PubMed ID: 4343125
[No Abstract] [Full Text] [Related]
19. [Rare case of a mixed mesodermal tumor of the uterus].
Khubenov A; Kolev Z; Ignatova S
Akush Ginekol (Sofiia); 1987; 26(4):78-81. PubMed ID: 2823624
[No Abstract] [Full Text] [Related]
20. A phase II trial of prolonged oral etoposide (VP-16) as second-line therapy for advanced and recurrent endometrial carcinoma: a Gynecologic Oncology Group study.
Rose PG; Blessing JA; Lewandowski GS; Creasman WT; Webster KD
Gynecol Oncol; 1996 Oct; 63(1):101-4. PubMed ID: 8898177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
